This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EPIRUS Biopharmaceuticals, Inc.
Drug Names(s): low dose amoxapine/dipyridamole
Description: CRx-150 is a combination of low doses of the approved drugs amoxapine and dipyridamole. Amoxapine is a tricyclic antidepressant, and dipyridamole is an anti-platelet drug. As an antidepressant, Amoxapine is thought to block the reuptake of norepinephrine and serotonin, and may block dopamine receptors, as well. Dipyridamole may inhibit red blood cell uptake of adenosine, phosphodiesterase, and thromboxane A2 formation. From preclinical studies, the low dose combination of the two is thought to inhibit the activity of inflammatory cytokines.
Epirus and Zalicus
In April 2014, Epirus and Zalicus announced that they have entered into a definitive agreement under which Epirus will merge with Zalicus in an all-stock transaction. Following closing, Zalicus will be re-named Epirus Biopharmaceuticals.
In July 2014, EPIRUS Biopharmaceuticals announced the completion of a merger with Zalicus. The combined company, which has been renamed EPIRUS Biopharmaceuticals, will focus on the business of EPIRUS and operate under the leadership of the EPIRUS management team.
Additional information available to subscribers only: